Experienced in Undescended Testicle

Chao-yuan F. Huang

National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, TW 
Experienced in Undescended Testicle
National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, TW 
OverviewLocationsClinical Research

Overview

Chao-yuan Huang practices in Hsinchu, Taiwan. Huang is rated as an Experienced expert by MediFind in the treatment of Undescended Testicle. Their top areas of expertise are Urothelial Cancer, Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Nephrectomy, and Prostatectomy.

Their clinical research consists of co-authoring 227 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Undescended Testicle.

Locations

National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, Taiwan
Other Locations
No.7, Chung Shan South Road, 100, Zhongzheng District, TPQ, Taiwan
No. 7, Chung Shan S. Road, Zhongzheng District, TPQ 10002, Taiwan
No. 7 Chung Shan South Road, TPQ 10002, Taiwan
7 Chung Shan South Road, TPQ 10002, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Patients With Advanced/Metastatic Renal Cell Carcinoma
An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Patients With Advanced/Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 26, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

227 Total Publications

Cabozantinib Sensitizes NSCLC Cells to Radiation by Inducing Ferroptosis via STAT3/MCL1/BECN1/SLC7A11 Axis Suppression.
Cabozantinib Sensitizes NSCLC Cells to Radiation by Inducing Ferroptosis via STAT3/MCL1/BECN1/SLC7A11 Axis Suppression.
Journal: Cancers
Published: July 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Huang's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile